当前位置: X-MOL 学术Nat. Rev. Drug. Disc. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Birgitte Volck
Nature Reviews Drug Discovery ( IF 122.7 ) Pub Date : 2017-05-31 , DOI: 10.1038/nrd.2017.105


Small patient populations are big business. In 2000, worldwide sales of orphan drugs for rare diseases accounted for just 6% of global prescription drug sales. Last year they accounted for US$114 billion in revenue and nearly 16% of total prescription drug sales, and they are on track to account for 21% of sales by 2022. For Birgitte Volck, head of rare disease R&D at GlaxoSmithKline, the explosion of this space has tracked with the arrival of a new era in rare disease drug discovery and development. She told Asher Mullard about how new drug modalities, the voice of the patient and genomics are reshaping the field.

中文翻译:

比尔吉特·沃尔克(Birgitte Volck)

病人人数少是大生意。2000年,罕见病孤儿药的全球销量仅占全球处方药销量的6%。去年,他们的收入达到了1,140亿美元,占处方药总销售额的近16%,并有望在2022年占到总销售额的21%。对于葛兰素史克(GlaxoSmithKline)罕见病研发部门负责人比尔吉特·沃尔克(Birgitte Volck)而言,随着稀有疾病药物发现和开发新时代的到来,这一领域也得到了追踪。她告诉阿舍·穆拉德(Asher Mullard)有关新药形式,患者声音和基因组学如何重塑这一领域的信息。
更新日期:2017-05-31
down
wechat
bug